Web Exclusives

In patients receiving treatment with CDK4/6 inhibitors, levels of neutralizing antibodies post-vaccination were similar to those in matched healthy controls. Read More ›

Although CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive/HER2-negative advanced breast cancer improve progression-free survival, this therapeutic intervention is also associated with higher rates of adverse events. Read More ›

To ensure the correct use of healthcare services, it is critical to invest in training nursing professionals who must educate patients on the timely recognition and management of complications. Read More ›

Study shows no compromise in treatment safety or efficacy associated with dose reduction of ribociclib. Read More ›

Research suggests that, when used in routine clinical practice in first or subsequent lines of treatment, ribociclib and palbociclib resulted in toxicity and efficacy outcomes in agreement with pivotal trial expectations. Read More ›

A recently released MYLUNG study found that most patients with untreated metastatic NSCLC tested for ≥1 biomarkers, but <50% of patients had ≥5 biomarker tests. Read More ›

Recently released clinical trial results evaluating the effect of early integration of interdisciplinary supportive care found improvement in quality of life, mood, and nutritional status in patients with NSCLC. Read More ›

Caregivers and patients report better understanding of precision medicine and reduced patient anxiety with implementation of a therapeutic patient education program. Read More ›

Study results reveal that KRAS G12C mutations vary according to sex and ethnicity in patients with cancer. Read More ›

Nivolumab plus chemotherapy in patients with advanced gastric cancer, esophageal adenocarcinoma, or gastroesophageal junction cancer led to significantly higher health-related quality-of-life scores than in patients receiving chemotherapy alone. Read More ›